Federico Hinestrosa - Concepedia

Author

Federico Hinestrosa

Orlando Immunology Center ORCID

Also Known As

F Hinestrosa, F. Hinestrosa, Federico Hinestrosa

Publications

2.5K

Citations

H-Index

Concepts

All Affiliations

Orlando Immunology Center Johns Hopkins University University of Pennsylvania University of Florida Bon Secours Liver Institute of Richmond

About

Federico Hinestrosa is an author at Orlando Immunology Center specializing in medicine, hepatitis, and viral hepatitis.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	439
2	Pharmacology	2	2	51
3	Epidemiology	1	1	179
4	Hepatology	1	1	41
5	Microbiology	1	1	22

Federico Hinestrosa

Publications

2.4K

Citations

H-Index

Page 1

	Year	Citations
Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection Mark Sulkowski, David Gardiner, M. Rodríguez‐Torres, New England Journal of Medicine	2014	1.2K
Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1 David Wyles, Peter Ruane, Mark Sulkowski, New England Journal of Medicine	2015	418
Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 Infection Mark Sulkowski, Hugo E. Vargas, Adrian M. Di Bisceglie, Gastroenterology Viral HepatitisReal-world PatientsHcv Genotype 1HepatitisVirology	2015	179
Sofosbuvir With Velpatasvir in Treatment-Naive Noncirrhotic Patients With Genotype 1 to 6 Hepatitis C Virus Infection Gregory T. Everson, William Towner, Mitchell Davis, Annals of Internal Medicine	2015	112
Sofosbuvir‐velpatasvir with ribavirin for 24 weeks in hepatitis C virus patients previously treated with a direct‐acting antiviral regimen Edward Gane, Mitchell L. Shiffman, K. Peter Etzkorn, Hepatology	2017	86
1422 POTENT VIRAL SUPPRESSION WITH ALL-ORAL COMBINATION OF DACLATASVIR (NS5A INHIBITOR) AND GS-7977 (NS5B INHIBITOR), +/− RIBAVIRIN, IN TREATMENT-NAIVE PATIENTS WITH CHRONIC HCV GT1, 2, OR 3 Mark Sulkowski, David Gardiner, E. Läwitz, Journal of Hepatology Viral Hepatitis+/− RibavirinAntiviral Drug DevelopmentAntiviral TherapyHepatitis	2012	80
1417 SUSTAINED VIROLOGIC RESPONSE WITH DACLATASVIR PLUS SOFOSBUVIR ± RIBAVIRIN (RBV) IN CHRONIC HCV GENOTYPE (GT) 1-INFECTED PATIENTS WHO PREVIOUSLY FAILED TELAPREVIR (TVR) OR BOCEPREVIR (BOC) Mark Sulkowski, David Gardiner, M. Rodríguez‐Torres, Journal of Hepatology Viral PersistenceHepatitis CViral HepatitisAntiviral TherapyHepatitis	2013	53
Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Genotype 1 Hepatitis C Virus Infection in an Open-Label, Phase 2 Trial Eric Lawitz, Nancy Reau, Federico Hinestrosa, Gastroenterology	2016	52
Real-world efficacy and safety of switching to bictegravir/emtricitabine/tenofovir alafenamide in older people living with HIV Charlotte-Paige Rolle, Vu Cong Nguyen, Kiran Patel, Medicine	2021	49
Efficacy of Glecaprevir and Pibrentasvir in Patients With Genotype 1 Hepatitis C Virus Infection With Treatment Failure After NS5A Inhibitor Plus Sofosbuvir Therapy Anna S. Lok, Mark Sulkowski, Jens Kort, Gastroenterology HepatologyHepatitis CViral HepatitisAntiviral Drug DevelopmentAntiviral Therapy	2019	41

Page 1